Novartis Ireland Limited

Lobbying Organisation Novartis Ireland Limited

Date published 21 Jan, 2026

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 Sep, 2025 to 31 Dec, 2025

Specific Details Forwarding letter to Dept of Health about access to innovative treatment for Irish patients

Intended results To secure a meeting with Minister for Health and or discussion about access to Novartis advanced therapy

Name of person primarily responsible for lobbying on this activity Eibhlín Mulroe

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (1)

Email sent on the 1st Sept, seeking follow up from Department of Health on a letter sent by Novartis (June 2025) to An Tanaiste. The letter is asking for a meeting to discuss timely access to Pluvicto for a small cohort of patients with advanced prostate cancer, in Ireland

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Simon Harris Tánaiste and Minister (Department of Foreign Affairs)

Jennifer Carroll MacNeill Minister (Department of Health)

Robert Watt Secretary General (Department of Health)

Dr Colm Henry Chief Clinical Officer (Health Service Executive)

Bernard Gloster Chief Executive Officer (Health Service Executive)

Robert Watt Secretary General (Department of Health)